Oruka Therapeutics, Inc. ORKA
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
1/9
Piotroski F — financial health
31.16
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$105.4M | — | -$88.4M | $471.9M |
| 2023 | $0 | -$5.3M | — | -$5.0M | $37.0M |
| 2022 | $0 | -$9.9M | — | -$10.9M | $41.7M |
| 2021 | $0 | -$19.3M | — | -$18.8M | $51.0M |
| 2020 | $0 | -$9.7M | — | -$7.7M | $46.5M |
| 2019 | $0 | -$5.5M | — | -$4.8M | $7.6M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Agarwal Arjun | Senior Vice President, Finance | 2026-06-22 | Sell | 888 | $80.01 |
| Agarwal Arjun | Senior Vice President, Finance | 2026-06-22 | Sell | 699 | $82.14 |
| Goncalves Joana | Chief Medical Officer | 2026-06-15 | Sell | 5,064 | $69.42 |
| Goncalves Joana | Chief Medical Officer | 2026-06-15 | Option exercise | 3,500 | $6.84 |
| Agarwal Arjun | Senior Vice President, Finance | 2026-06-15 | Sell | 395 | $69.69 |
| Goncalves Joana | Chief Medical Officer | 2026-06-15 | Sell | 1,636 | $68.38 |
| Goncalves Joana | Chief Medical Officer | 2026-06-15 | Option exercise | 3,500 | $7.80 |
| Goncalves Joana | Chief Medical Officer | 2026-06-15 | Sell | 300 | $70.62 |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 31.16 (safe)
- Working capital / assets 0.672
- Retained earnings / assets -0.387
- EBIT / assets -0.25
- Equity / liabilities 28.281
Source: SEC EDGAR filings · CIK 0000907654 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.